Episode #611: Outpatient Innovation-Dr. Munir Ghesani Discusses Theranostics, Expansion, and Clinical Trials

In this episode, we sit down with Dr. Munir Ghesani, Chief Medical Director at United Theranostics, to explore the cutting edge of personalized cancer treatment and the business of scaling innovative healthcare delivery. Dr. Ghesani discusses his three decades long path in New York’s academic medicine scene to leading a fast-growing outpatient theranostics group, detailing why he left academia, what makes theranostics uniquely effective for patients, and how United Theranostics is building a national footprint through a decentralized, community-based model. 

We’ll unpack how their patient-first strategy is shaking up referral dynamics, why community settings are the future of cancer care, and what it takes to recruit medical talent and manage rapid clinical expansion. Plus, Dr. Ghesani reveals the business challenges of clinical trials, payer dynamics, and how a rigorous approach to risk keeps innovation on track. Whether you’re in healthcare, investing, or looking to build a next-gen medical services brand, this episode connects patient outcomes, operational strategy, and smart growth in healthcare.

Key themes discussed

• Transition from academia to private theranostics practice
• Personalized, patient-centered cancer treatment models
• Patient access and geographic convenience
• Clinical trials and innovation in care delivery
• Recruitment and training for high-growth clinic expansion
• Collaborative physician partnerships vs. pure referral
• Regulation, quality control, and risk management in trials
  
  

A Few Key Takeaways

1.Theranostics-Personalized, Precision Medicine: Theranostics is revolutionizing patient care by merging diagnostics and therapeutics to deliver highly personalized treatment plans, particularly in oncology. Unlike traditional, one-size-fits-all treatments, theranostics involves tailored scanning to target therapies specifically to affected areas, ensuring treatments are both targeted and trackable for efficacy 05:07 06:02.

2. Outpatient Model Drives Access and Community Impact: The majority of cancer care occurs outside of major academic centers, with about 80% delivered in community settings. United Theranostics focuses on suburban locations, making advanced treatments more accessible and convenient for patients who would otherwise travel significant distances to academic hubs 08:42 14:13.

3. Dual Audience Strategy: Physicians & Patients: United Theranostics balances building awareness and trust among both referring physicians and patients. While most referrals come from medical professionals, growing patient awareness is generating direct demand, reinforcing the need for strong brand positioning, serving as both a partner to doctors and a recognized consumer brand in its space 10:05.

4. Scaling Without Compromising Quality: With ambitions for 50 clinics in every state within seven years, United Theranostics is scaling through greenfield development and a strong recruitment pipeline from academic institutions. The company prioritizes training, regulatory compliance, and quality control, resisting the urge to rapidly acquire or retrofit existing practices 14:29 15:25.

5. Clinical Trials as a Competitive Advantage: Clinical trial partnerships are fueling United Theranostics’ growth and reputation, drawing patients locally and nationally for cutting-edge, not-yet-FDA-approved treatments (covered by drug companies). The organization’s comfort with complexity and strong academic roots allow it to handle demanding cases, setting it apart from less equipped competitors 18:28 19:58.

Resources:

• Dr. Munir Ghesani: https://www.linkedin.com/in/munir-ghesani-md-facnm-facr-fsnmmi-19b29728 
• United Theranostics: https://www.unitedtheranostics.com/ 
• Integrity Square: https://www.integritysq.com
• Prospect Wizard: https://www.theprospectwizard.com
• Promotion Vault: https://www.promotionvault.com
• HigherDose: https://www.higherdose.com